Geneva Capital Management LLC Purchases 37,392 Shares of Certara, Inc. (NASDAQ:CERT)

Geneva Capital Management LLC increased its position in shares of Certara, Inc. (NASDAQ:CERT) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,510,209 shares of the company’s stock after buying an additional 37,392 shares during the period. Geneva Capital Management LLC owned about 3.42% of Certara worth $64,525,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Clearbridge Investments LLC lifted its holdings in Certara by 0.8% during the first quarter. Clearbridge Investments LLC now owns 4,173,195 shares of the company’s stock worth $74,617,000 after buying an additional 32,846 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after acquiring an additional 273,095 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Certara by 9.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after purchasing an additional 248,448 shares during the last quarter. Daventry Group LP boosted its position in Certara by 153.0% during the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after purchasing an additional 791,405 shares in the last quarter. Finally, Bamco Inc. NY grew its stake in Certara by 1.4% in the first quarter. Bamco Inc. NY now owns 1,085,950 shares of the company’s stock valued at $19,417,000 after purchasing an additional 15,000 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Certara Price Performance

Shares of Certara stock opened at $10.60 on Wednesday. Certara, Inc. has a 52 week low of $9.99 and a 52 week high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average price of $10.97 and a 200 day moving average price of $13.58.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.06 earnings per share. As a group, equities research analysts predict that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, September 27th. Robert W. Baird decreased their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Finally, Barclays lowered their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.